|
1
|
Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome.
|
Clin Chem
|
2005
|
1.62
|
|
2
|
Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls.
|
Hum Reprod
|
2005
|
1.43
|
|
3
|
Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.
|
Am J Physiol Endocrinol Metab
|
2008
|
1.27
|
|
4
|
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
|
Hum Reprod
|
2006
|
1.10
|
|
5
|
Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
|
Hum Reprod
|
2011
|
1.00
|
|
6
|
Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
|
Clin Endocrinol (Oxf)
|
2008
|
0.93
|
|
7
|
Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome.
|
J Bone Miner Metab
|
2010
|
0.93
|
|
8
|
The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
|
Gynecol Endocrinol
|
2010
|
0.90
|
|
9
|
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
|
Fertil Steril
|
2007
|
0.89
|
|
10
|
Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome.
|
Eur J Endocrinol
|
2009
|
0.89
|
|
11
|
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
|
Endocr J
|
2011
|
0.86
|
|
12
|
Genetic variants in TCF7L2 and KCNJ11 genes in a Greek population with polycystic ovary syndrome.
|
Gynecol Endocrinol
|
2008
|
0.85
|
|
13
|
Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
|
Eur J Intern Med
|
2008
|
0.85
|
|
14
|
Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.
|
Endocrine
|
2013
|
0.85
|
|
15
|
The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.
|
Clin Endocrinol (Oxf)
|
2013
|
0.84
|
|
16
|
Serum luteinizing hormone levels are markedly increased and significantly correlated with Delta 4-androstenedione levels in lean women with polycystic ovary syndrome.
|
Fertil Steril
|
2005
|
0.84
|
|
17
|
Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
|
Metabolism
|
2007
|
0.83
|
|
18
|
The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration.
|
Hormones (Athens)
|
2013
|
0.83
|
|
19
|
Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
|
Fertil Steril
|
2006
|
0.83
|
|
20
|
Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.
|
Fertil Steril
|
2011
|
0.83
|
|
21
|
Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
|
Clin Endocrinol (Oxf)
|
2007
|
0.83
|
|
22
|
Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
|
Endocr J
|
2011
|
0.82
|
|
23
|
Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact?
|
Gynecol Endocrinol
|
2010
|
0.81
|
|
24
|
Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome.
|
Eur J Endocrinol
|
2013
|
0.80
|
|
25
|
The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study.
|
Reprod Biol Endocrinol
|
2010
|
0.80
|
|
26
|
The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.
|
Fertil Steril
|
2008
|
0.80
|
|
27
|
Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery.
|
Front Horm Res
|
2012
|
0.79
|
|
28
|
Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).
|
Gynecol Endocrinol
|
2012
|
0.79
|
|
29
|
Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels.
|
Med Hypotheses
|
2011
|
0.79
|
|
30
|
Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
|
Hum Reprod
|
2013
|
0.79
|
|
31
|
Prevalence of metabolic syndrome in women with polycystic ovary syndrome.
|
Clin Endocrinol (Oxf)
|
2013
|
0.79
|
|
32
|
Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome.
|
Hormones (Athens)
|
2015
|
0.78
|
|
33
|
Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome.
|
Hormones (Athens)
|
2012
|
0.78
|
|
34
|
The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome.
|
Atherosclerosis
|
2007
|
0.78
|
|
35
|
Indices of insulin sensitivity, beta cell function and serum proinsulin levels in the polycystic ovary syndrome.
|
Eur J Obstet Gynecol Reprod Biol
|
2006
|
0.78
|
|
36
|
The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome.
|
Eur J Endocrinol
|
2013
|
0.78
|
|
37
|
The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria.
|
Obes Facts
|
2011
|
0.77
|
|
38
|
Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome.
|
Eur J Obstet Gynecol Reprod Biol
|
2010
|
0.77
|
|
39
|
Calcium homeostasis and anovulatory infertility.
|
Hum Reprod
|
2007
|
0.77
|
|
40
|
Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels.
|
Eur J Endocrinol
|
2011
|
0.77
|
|
41
|
Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome.
|
Gynecol Endocrinol
|
2012
|
0.77
|
|
42
|
Serum AMH, FSH, and LH levels in PCOS.
|
Fertil Steril
|
2010
|
0.77
|
|
43
|
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
|
Gynecol Endocrinol
|
2011
|
0.77
|
|
44
|
Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
|
Hormones (Athens)
|
2014
|
0.76
|
|
45
|
Effect of hyperglycemia and hyperinsulinemia on glutathione peroxidase activity in non-obese women with polycystic ovary syndrome.
|
Hormones (Athens)
|
2015
|
0.76
|
|
46
|
Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients.
|
Fertil Steril
|
2009
|
0.76
|
|
47
|
Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance.
|
Fertil Steril
|
2009
|
0.76
|
|
48
|
Serum and seminal plasma ghrelin levels in men with normospermia and dyspermia.
|
Gynecol Endocrinol
|
2008
|
0.76
|
|
49
|
The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers.
|
Hormones (Athens)
|
2015
|
0.76
|
|
50
|
Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome.
|
Gynecol Endocrinol
|
2013
|
0.75
|
|
51
|
Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
|
Fertil Steril
|
2009
|
0.75
|
|
52
|
The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia.
|
Fertil Steril
|
2007
|
0.75
|
|
53
|
Long-term follow-up of combined pituitary hormone deficiency in two siblings with a Prophet of Pit-1 gene mutation.
|
Gynecol Endocrinol
|
2006
|
0.75
|
|
54
|
Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.
|
Eur J Obstet Gynecol Reprod Biol
|
2012
|
0.75
|